The Role of RAC2 and PTTG1 in Cancer Biology
Cells · 23.02.2025 · 14 (5) · 330
DOI: 10.3390/cells14050330 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 23.02.2025. Verfasst von Katarzyna Rakoczy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Wroclaw Medical University, Pasteura 1, 50-367 Wroclaw, Poland. Hauptthemen laut MEDLINE: Securin, Neoplasms, rac GTP-Binding Proteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Statutory Subsidy of Wroclaw Medical University.
Abstract (Originalsprache)
Several molecular pathways are likely involved in the regulation of cancer stem cells (CSCs) via Ras-associated C3 botulinum toxin substrate 2, RAC2, and pituitary tumor-transforming gene 1 product, PTTG1, given their roles in cellular signaling, survival, proliferation, and metastasis. RAC2 is a member of the Rho GTPase family and plays a crucial role in actin cytoskeleton dynamics, reactive oxygen species production, and cell migration, contributing to epithelial–mesenchymal transition (EMT), immune evasion, and therapy resistance. PTTG1, also known as human securin, regulates key processes such as cell cycle progression, apoptosis suppression, and EMT, promoting metastasis and enhancing cancer cell survival. This article aims to describe the molecular pathways involved in the proliferation, invasiveness, and drug response of cancer cells through RAC2 and PTTG1, aiming to clarify their respective roles in neoplastic process dependencies. Both proteins are involved in critical signaling pathways, including PI3K/AKT, TGF-β, and NF-κB, which facilitate tumor progression by modulating CSC properties, angiogenesis, and immune response. This review highlights the molecular mechanisms by which RAC2 and PTTG1 influence tumorigenesis and describes their potential and efficacy as prognostic biomarkers and therapeutic targets in managing various neoplasms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Wroclaw Medical University, Pasteura 1, 50-367 Wroclaw, Poland.
- Department of Molecular and Cellular Biology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211a, 50-556 Wroclaw, Poland.
- Department of Immunology and Bioelectrochemistry, State Research Institute Centre for Innovative Medicine, Santariškių g. 5, LT-08406 Vilnius, Lithuania.
ORCID-Profile: Natalia Szymańska, Jakub Stecko, Michał Kisiel, Jakub Sleziak, Agnieszka Gajewska-Naryniecka, Julita Kulbacka
Förderung
- Statutory Subsidy of Wroclaw Medical University
Zitieren
APA
Rakoczy, K., Szymańska, N., Stecko, J., Kisiel, M., Sleziak, J., Gajewska-Naryniecka, A., & Kulbacka, J. (2025). The Role of RAC2 and PTTG1 in Cancer Biology. Cells, 14(5), 330. https://doi.org/10.3390/cells14050330
Vancouver
Rakoczy K, Szymańska N, Stecko J, Kisiel M, Sleziak J, Gajewska-Naryniecka A, et al. The Role of RAC2 and PTTG1 in Cancer Biology. Cells. 2025;14(5):330. doi:10.3390/cells14050330
BibTeX
@article{Rakoczy2025,
author = {Rakoczy, Katarzyna and Szymańska, Natalia and Stecko, Jakub and Kisiel, Michał and Sleziak, Jakub and Gajewska-Naryniecka, Agnieszka and Kulbacka, Julita},
title = {The Role of RAC2 and PTTG1 in Cancer Biology},
journal = {Cells},
year = {2025},
volume = {14},
number = {5},
pages = {330},
doi = {10.3390/cells14050330}
}
EUVIMED